Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial

BACKGROUND: The De-ESCALaTE HPV trial confirmed the dominance of cisplatin over cetuximab for tumour control in patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC). Here, we present the analysis of health-related quality of life (HRQoL), resource use, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, David A., Mistry, Pankaj, Dalby, Matthew, Fulton-Lieuw, Tessa, Kong, Anthony H., Dunn, Janet, Mehanna, Hisham M., Gray, Alastair M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science Ltd 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947474/
https://www.ncbi.nlm.nih.gov/pubmed/31794928
http://dx.doi.org/10.1016/j.ejca.2019.10.025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947474/
https://www.ncbi.nlm.nih.gov/pubmed/31794928
http://dx.doi.org/10.1016/j.ejca.2019.10.025

Ejemplares similares